期刊文献+

吡美莫司的合成及其结构鉴定 被引量:1

Synthesis and identification of pimecrolimus
下载PDF
导出
摘要 以子囊霉素为原料,经酯化、氯化合成吡美莫司;粗品经柱层析、重结晶得到纯化,最终收率41.1%,纯度95.3%;合成产品经熔点,IR,1HNMR,13CNMR,ESI/MS等分析手段进行鉴定。 Pimecrolimus was synthesized by using ascomycin as a starting material through esterification and chlorination. The pure products were obtained by columnchromatography and crystallization. (the finally yield was 41.1%, the purity was 95.3 % ) The structure was confirmed by melting point, IR, 1H NMR, 13C NMR and ESI/ MS analysis.
出处 《海峡药学》 2010年第8期245-247,共3页 Strait Pharmaceutical Journal
关键词 吡美莫司 合成 纯化 鉴定 Pimecrolimus Synthesis Purification Identification
  • 引文网络
  • 相关文献

参考文献13

  • 1Ruzicka T, Assmann T, Homey B. Tacrolimus: The drug for the turn of the millennium [J]. Arch Dermatol, 1999, 135 (5) : 574.
  • 2Schreiber SL, Crabtree GR. The mechanism of action of cyclosporing A and FK506 [J]. Immunol Today, 1992, 13 : 136.
  • 3Eichenfield LF, Beck L.Elidel ( pimecrolimus ) cream 1% : a non-steroidal topical agent for the treatment of atopic dermatitis [J]. J Allergy Clin Immunol, 2003, 111: 1153-1168.
  • 4Luger T, Van Leent E J, Graeber M , et al. SDZ ASM 981: anmerging safe and effective treatment for atopie dermatitis [J]. Br J Dermatol, 2001, 144 : 788-794.
  • 5Honda Y, Okubo Y, Koga M. Relationship between levels of solubleinterleukin-2 receptors and the types and activity of vitili-go[J].J Dermatol, 1997, 24(9) : 561-563.
  • 6Gupta AK, Chow M. Pimeerolimus: a review [J].J Eur Acad Dermatol Venereol, 2003, 17(5) :493-503.
  • 7Zuberbier T, Chong SU, Grunow K, et al. The ascomyein macrolactam pimecrolimus (Elidel, SDZ ASM 981 ) is a potent inhibitor of mediator release from human dermalmast cells and peripheral blood basophilsl [J].J Allergy Clin lmmunol, 2001, 108 (2) :275-280.
  • 8Baumann Karl (AT), EmmerGerhard (AT). Heteroatoms containing tricyclic compounds. EP 0427680.
  • 9Grassberger Maximilian ( AT ), Horvath Amarylla ( AT ). Heteroatoms-Containing Tricyclie Compounds. WO2006040111.
  • 10Gyollai V, Szabo C.2006.Methods for preparing pirnecrolimus. WO2006060614.

同被引文献8

  • 1Grassberger M, Baumruker T, Enz A et al. A novel antiinflammatory drug, SDZ ASM 981, for the treatment of skindisease : in vitro pharma- cology[J]. Br J Dermatol,1999,141:263-273.
  • 2Gupta AK, Chow M. Pimecrolimus : a review [J]. J Eur Acad Dermatol Venereo1,2003 ,17 :493-503.
  • 3Zuberbier T, Chong SU, Grunow K et al. The ascomycin macrohibitor of mediator release from human dermal mast ceils and peripheral blood basophilsl [ J ]. J Allergy Clin Immunol,2001,108 : 275-280.
  • 4应加银,黄楷,范丹,张祝兰,郑卫.吡美莫司的合成工艺研究[C].2011抗感染药物与耐药菌防控专题研讨会论文集.
  • 5Grassberger Maximilian ( AT), Horvath Amarylla (AT). Heteroatoms- Containing Tricyclic Compounds(P). WO2006040111. 2006-04-20.
  • 6Baumann Karl, EmmerGerhard. Heteroatoms containing tricyclic com- pounds(P). EP0427680. 1991-05-15.
  • 7Gyollai V, Szabo C. Method for preparing pimecrolimus (P). WO2006060614. 2006-06-08.
  • 8Dosenbach C, Grassberger M, Hartmann O, Horvath A, Mutz J.-P. , Penn G, Pfeffer S, Wieckhusen D. Crystalline macrolides and process for their preparation(P). WO9901458. 1999-01-14.

引证文献1

;
使用帮助 返回顶部